207 related articles for article (PubMed ID: 29294360)
1. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Rogliani P; Ora J; Puxeddu E; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2018 Apr; 49():20-26. PubMed ID: 29294360
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
[TBL] [Abstract][Full Text] [Related]
3. Physiological effects of roflumilast at rest and during exercise in COPD.
O'Donnell DE; Bredenbröker D; Brose M; Webb KA
Eur Respir J; 2012 May; 39(5):1104-12. PubMed ID: 21965226
[TBL] [Abstract][Full Text] [Related]
4. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
5. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
Beeh KM; Singh D; Di Scala L; Drollmann A
Int J Chron Obstruct Pulmon Dis; 2012; 7():503-13. PubMed ID: 22973092
[TBL] [Abstract][Full Text] [Related]
6. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
8. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P
Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253
[TBL] [Abstract][Full Text] [Related]
9. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
10. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
[TBL] [Abstract][Full Text] [Related]
11. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
Vos W; Hajian B; De Backer J; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer W
Int J Chron Obstruct Pulmon Dis; 2016; 11():263-71. PubMed ID: 26917956
[TBL] [Abstract][Full Text] [Related]
12. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
13. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Kiff C; Ruiz S; Varol N; Gibson D; Davies A; Purkayastha D
Int J Chron Obstruct Pulmon Dis; 2018; 13():2707-2720. PubMed ID: 30214188
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
17. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
Carter NJ
Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
[TBL] [Abstract][Full Text] [Related]
18. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
[No Abstract] [Full Text] [Related]
19. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
